Histamine H
4 receptor (H
4R) has an important role in immune and inflammatory diseases [
1]. A pivotal study by Dunford et al. [
2] has shown that treatment with the H
4R antagonist JNJ7777120 shows a similar pattern of efficacy in a mouse model of asthma compared to the H
4R knock-out mice. However, as this compound has impaired pharmacokinetic properties [
3], its relevance as a pharmacological tool is limited. In our efforts to find new active H
4R substances, we have identified UR-60427 from the lead compounds investigated at Palau Pharma as a new ligand, and its pharmacological profile is described here. …
